April 20, 2017
AMSTERDAM — Understanding the impacts of fibrosis, drug–drug interactions with direct-acting antiviral therapies, and the pitfalls of immunosuppression can aid clinicians in treating liver transplantation candidates or recipients, according to data presented at the International Liver Congress.
Michael Charlton, MD, a transplant hepatologist and director of the Intermountain Transplant and Regenerative Medicine Center, said that the frequency of wait-listing for transplantation for patients with HCV has decreased considerably in recent years. “The indication is now highest for alcohol use,” he said. “The indications for NASH have remained relatively stable.”